• Nenhum resultado encontrado

Braz. J. Pharm. Sci. vol.47 número4

N/A
N/A
Protected

Academic year: 2018

Share "Braz. J. Pharm. Sci. vol.47 número4"

Copied!
10
0
0

Texto

Loading

Imagem

FIGURE 3  -  HMG-CoA reductase inhibitors.
Table I shows molecular pharmacokinetic properties  calculated for the β-adrenergic antagonists with  Molinspi-ration and Osiris.
Table I shows that atenolol received the worst drug score,  0.27. This probably occurred because atenolol has toxicity  risks (mutagenic, irritant and reproductive) according to  Osiris (Figure 4)
TABLE III  -  Molecular pharmacokinetics properties calculated for the HMG-CoA reductase inhibitors using Molinspiration and Osiris

Referências

Documentos relacionados

In this study, an alternating copolymer of maleic anhydride and N -vinyl- 2-pyrrolidone was modified by reaction with aliphatic amines and alcohols of varying length of the

the highest percentage of ines, repose angle, compressi - bility index and friability, and with the lowest percentage of coarse fraction, mean granule size, and 50% and 90%

In this present study to prepare olanzapine FDT, DSC, XRD, and SEM analyses were performed to de- termine the physicochemical properties of the FDT and then compare these

Among the 71.8% of respondents who had already used topic nasal decongestants, 64.3% had used this medication for at least 15 days and 64.6% had started using it due to

The results indicated that nanoemulsions are promising vehicles for transdermal delivery of glycyrrhizin through human cadaver skin, without the use of additional

In order to optimise the separation of these preservatives, the effects of mobile phase composition on the separation were evaluated, as well as the applied voltage and

The results of this study revealed that nonadherence to treatment by patients with mental disorders is a serious and persistent problem correlated with lack of information

Access to medicines is an indicator of both quality and effectiveness of the public health system, as well as a determinant factor for patient adherence to prescription